RT Journal Article
SR Electronic
T1 Auto-antibodies to p53 and the Subsequent Development of Colorectal Cancer in a U.S. Prospective Cohort Consortium
JF Cancer Epidemiology Biomarkers & Prevention
JO Cancer Epidemiol Biomarkers Prev
FD American Association for Cancer Research
DO 10.1158/1055-9965.EPI-20-0780
A1 Butt, Julia
A1 Blot, William J.
A1 Visvanathan, Kala
A1 Le Marchand, Loïc
A1 Wilkens, Lynne R.
A1 Chen, Yu
A1 Sesso, Howard D.
A1 Teras, Lauren
A1 Ryser, Marc D.
A1 Hyslop, Terry
A1 Wassertheil-Smoller, Sylvia
A1 Tinker, Lesley F.
A1 Potter, John D.
A1 Song, Mingyang
A1 Berndt, Sonja I.
A1 Waterboer, Tim
A1 Pawlita, Michael
A1 Epplein, Meira
YR 2020
UL http://cebp.aacrjournals.org/content/early/2020/10/23/1055-9965.EPI-20-0780.abstract
AB Background: Auto-antibodies to tumor suppressor p53 are found in a subset of patients with colorectal cancer. A recent prospective study in the United States has reported a significant 1.8-fold increased odds for colorectal cancer development with prediagnostic seropositivity to p53. In this study, we sought to examine this association in a U.S. colorectal cancer cohort consortium to evaluate the potential utility of p53 auto-antibodies as an early biomarker for colorectal cancer.Methods: Auto-antibodies to p53 were measured in prediagnostic blood samples of 3,702 incident colorectal cancer cases and 3,702 controls, matched by age, race, and sex, from 9 U.S. prospective cohorts. The association of seropositivity to p53 with colorectal cancer risk, overall and by time between blood draw and diagnosis, was determined by conditional logistic regression.Results: Overall, 5% of controls and 7% of cases were seropositive to p53, resulting in a statistically significant 33% increased colorectal cancer risk [odds ratio (OR), 1.33; 95% confidence interval (CI), 1.09–1.61]. By follow-up time, the association was only significant with colorectal cancer diagnoses within 4 years after blood draw (OR, 2.27; 95% CI, 1.62–3.19), but not thereafter (OR, 0.97; 95% CI, 0.76–1.24).Conclusions: In this large consortium of prospective cohorts, we found that prediagnostic seropositivity to tumor suppressor p53 was significantly associated with an over 2-fold increased odds of developing colorectal cancer within 4 years after blood draw.Impact: Our finding suggests that p53 seropositivity may not be a useful predictor of long-term colorectal cancer risk; however, it might be considered as a marker to aid in the early diagnosis of colorectal cancer.